Regulatory News
Wednesday, January 11, 2017
BRIEF-Tesaro receives complete response letter for Rolapitant IV from U.S. FDA
* Tesaro receives complete response letter for Rolapitant IV from U.S. FDA
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
View mobile version
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment